{"id":67950,"date":"2026-10-23T06:45:38","date_gmt":"2026-10-23T01:15:38","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=67950"},"modified":"2026-10-23T07:09:32","modified_gmt":"2026-10-23T01:39:32","slug":"new-series-of-interactive-cardiology-mcqs-9","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/","title":{"rendered":"New Series of Interactive Cardiology MCQs 9"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Please ignore the questions with incomplete options as they have errors in code!<\/strong><\/p>\n\n\n\n<!-- \n  INSTRUCTIONS FOR WORDPRESS:\n  1. Add a new \"Custom HTML\" block in your WordPress editor.\n  2. Copy everything from line 1 to the end of this file.\n  3. Paste it into the Custom HTML block.\n  4. Preview or Publish the post to see the interactive MCQs in action.\n-->\n\n<script src=\"https:\/\/cdn.tailwindcss.com\"><\/script>\n<script>\n  tailwind.config = {\n    corePlugins: {\n      preflight: false, \/\/ Ensures maximum compatibility with WordPress themes\n    }\n  }\n<\/script>\n\n<div class=\"cardio-quiz-wrapper font-sans bg-slate-950 text-slate-200 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-cyan-900\/50\" style=\"box-sizing: border-box; font-family: 'Inter', system-ui, sans-serif;\">\n  \n  <!-- Ambient Dark Medical Theme Glows -->\n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-20 bg-[radial-gradient(ellipse_at_top,_var(--tw-gradient-stops))] from-cyan-600 via-slate-900 to-slate-950\"><\/div>\n  \n  <!-- Header Banner -->\n  <div class=\"relative text-center pb-6 border-b border-cyan-900\/50 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-cyan-600 to-teal-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-widest shadow-lg shadow-cyan-900\/50 mb-4\">\n      Advanced Clinical Series\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-400 to-teal-300 m-0 drop-shadow-md\">\n      Cardiology MCQs: Part 9\n    <\/h1>\n    <p class=\"text-sm md:text-base text-slate-400 mt-3 max-w-2xl mx-auto font-medium\">\n      Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials.\n    <\/p>\n  <\/div>\n\n  <!-- Sticky Live Scoreboard -->\n  <div class=\"sticky top-4 z-40 bg-slate-900\/85 backdrop-blur-xl border border-cyan-800\/60 rounded-2xl p-4 md:p-5 mb-8 shadow-xl shadow-cyan-900\/20 flex flex-wrap items-center justify-between gap-4 transition-all\">\n    <div class=\"flex items-center gap-4\">\n      <div class=\"w-12 h-12 rounded-full bg-cyan-950 flex items-center justify-center border border-cyan-700 shadow-inner text-cyan-400\">\n        <svg class=\"w-6 h-6\" fill=\"none\" stroke=\"currentColor\" viewBox=\"0 0 24 24\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path stroke-linecap=\"round\" stroke-linejoin=\"round\" stroke-width=\"2\" d=\"M9 12l2 2 4-4M7.835 4.697a3.42 3.42 0 001.946-.806 3.42 3.42 0 014.438 0 3.42 3.42 0 001.946.806 3.42 3.42 0 013.138 3.138 3.42 3.42 0 00.806 1.946 3.42 3.42 0 010 4.438 3.42 3.42 0 00-.806 1.946 3.42 3.42 0 01-3.138 3.138 3.42 3.42 0 00-1.946.806 3.42 3.42 0 01-4.438 0 3.42 3.42 0 00-1.946-.806 3.42 3.42 0 01-3.138-3.138 3.42 3.42 0 00-.806-1.946 3.42 3.42 0 010-4.438 3.42 3.42 0 00.806-1.946 3.42 3.42 0 013.138-3.138z\"><\/path><\/svg>\n      <\/div>\n      <div>\n        <div class=\"text-[10px] md:text-xs uppercase font-extrabold tracking-widest text-teal-500\">Live Score<\/div>\n        <div class=\"text-xl md:text-3xl font-black text-slate-100 flex items-baseline gap-1\">\n          <span id=\"score-correct\">0<\/span>\n          <span class=\"text-slate-500 text-sm md:text-lg font-bold\">\/ 25<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-3 bg-slate-950\/80 px-4 py-2 rounded-xl border border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-widest hidden sm:inline\">Progress<\/span>\n      <div class=\"w-24 md:w-32 bg-slate-800 h-2.5 rounded-full overflow-hidden\">\n        <div id=\"progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-teal-500 h-full w-0 transition-all duration-500 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-cyan-400\"><span id=\"score-answered\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <!-- Quiz Questions Container -->\n  <div class=\"space-y-6 relative\" id=\"mcq-container\">\n    \n    <!-- Q1 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">1.<\/span> \n        In the cardiac catheterization lab, measuring the instantaneous wave-free ratio (iFR) is often preferred over Fractional Flow Reserve (FFR) because iFR:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"true\" data-explanation=\"iFR measures the translesional pressure ratio during a specific period in diastole (the wave-free period) when microvascular resistance is naturally minimized, thereby avoiding the need to induce maximal hyperemia with adenosine.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Does not require the administration of a hyperemic agent like adenosine<\/button>\n        <button data-correct=\"false\" data-explanation=\"FFR uses the entire cardiac cycle during maximal hyperemia. iFR uses a specific diastolic wave-free period.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Evaluates flow throughout the entire cardiac cycle<\/button>\n        <button data-correct=\"false\" data-explanation=\"Neither FFR nor iFR relies on thermodilution; both use a pressure wire. Coronary Flow Reserve (CFR) can be measured via thermodilution.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Utilizes thermodilution rather than a pressure wire<\/button>\n        <button data-correct=\"false\" data-explanation=\"Both iFR and FFR are utilized to assess the hemodynamic significance of intermediate lesions. iFR is not exclusively for bypass grafts.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Is only validated for assessing lesions in saphenous vein grafts<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">2.<\/span> \n        A patient with severe aortic stenosis presents with a calculated Aortic Valve Area (AVA) of 0.8 cm2, a mean transvalvular gradient of 25 mmHg, a Left Ventricular Ejection Fraction (LVEF) of 60%, and a stroke volume index (SVi) of 28 mL\/m2. This pattern best describes:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Classical low-flow, low-gradient AS occurs in the setting of a REDUCED ejection fraction (LVEF < 50%), requiring dobutamine stress echo to differentiate true from pseudo-severe AS.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Classical low-flow, low-gradient severe AS<\/button>\n        <button data-correct=\"true\" data-explanation=\"Paradoxical low-flow, low-gradient severe AS occurs when the AVA is severe (<=1.0 cm2), the gradient is low (<40 mmHg), but the LVEF is PRESERVED (>=50%). It is driven by a small LV cavity size and concentric hypertrophy leading to a low stroke volume index (<35 mL\/m2).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Paradoxical low-flow, low-gradient severe AS<\/button>\n        <button data-correct=\"false\" data-explanation=\"Normal flow, low gradient severe AS would have an SVi > 35 mL\/m2. This patient&#8217;s SVi is 28 (low flow).&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>C) Normal flow, low gradient severe AS<\/button>\n        <button data-correct=\"false\" data-explanation=\"High-gradient severe AS is defined by a mean transvalvular gradient >= 40 mmHg or a peak velocity >= 4.0 m\/s.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>D) High-gradient severe AS<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">3.<\/span> \n        The LoDoCo2 (Low-Dose Colchicine) trial demonstrated that adding low-dose colchicine (0.5 mg daily) in patients with chronic coronary disease significantly reduced:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"true\" data-explanation=\"The LoDoCo2 trial showed that 0.5 mg of colchicine daily in patients with chronic coronary disease significantly reduced the primary composite endpoint of CV death, spontaneous MI, ischemic stroke, or ischemia-driven coronary revascularization, highlighting the role of inflammation in CAD.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) A composite of CV death, MI, ischemic stroke, or ischemia-driven revascularization<\/button>\n        <button data-correct=\"false\" data-explanation=\"While it reduced composite ischemic events, colchicine did not show a statistically significant reduction in all-cause mortality alone in this trial.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) All-cause mortality alone<\/button>\n        <button data-correct=\"false\" data-explanation=\"Colchicine does not reverse calcification; its mechanism in CAD is anti-inflammatory.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) The progression of coronary artery calcium (CAC) scores<\/button>\n        <button data-correct=\"false\" data-explanation=\"Colchicine has no direct antithrombotic effect on platelet aggregation (unlike aspirin or P2Y12 inhibitors).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Platelet aggregation rates in clopidogrel non-responders<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">4.<\/span> \n        In patients with suspected Transthyretin Cardiac Amyloidosis (ATTR-CA), a Technetium-99m Pyrophosphate (Tc-99m PYP) scan is considered highly specific for ATTR if the cardiac uptake grade is:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Grade 0 (no uptake) and Grade 1 (uptake less than bone) are considered negative for ATTR-CA.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Grade 1 or less<\/button>\n        <button data-correct=\"true\" data-explanation=\"A Grade 2 (uptake equal to bone) or Grade 3 (uptake greater than bone) on a Tc-99m PYP scan is highly specific (approaching 100%) for ATTR cardiac amyloidosis, provided light-chain (AL) amyloidosis has been ruled out via serum\/urine studies.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Grade 2 or 3<\/button>\n        <button data-correct=\"false\" data-explanation=\"Grade 3 is positive, but Grade 2 is also considered positive in the appropriate clinical context.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Only Grade 3<\/button>\n        <button data-correct=\"false\" data-explanation=\"Cardiac uptake grading compares the heart to the ribs\/bone on the scan, not to the liver.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Greater than liver uptake, regardless of bone grade<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">5.<\/span> \n        Idiopathic left ventricular tachycardia (Belhassen VT) characteristically originates from the posterior fascicle of the left bundle branch and is acutely terminated by which medication?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Adenosine is highly effective for terminating AV nodal dependent tachycardias (AVNRT\/AVRT) and RVOT VT, but not typically fascicular VT.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Adenosine<\/button>\n        <button data-correct=\"true\" data-explanation=\"Idiopathic fascicular VT (Belhassen VT) is classically a reentrant tachycardia involving the calcium channels of the Purkinje network, making it exquisitely sensitive to, and terminable by, intravenous Verapamil.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Verapamil<\/button>\n        <button data-correct=\"false\" data-explanation=\"Lidocaine is a Class 1B agent useful for ischemic ventricular tachycardia, but fascicular VT is specifically calcium-channel dependent.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Lidocaine<\/button>\n        <button data-correct=\"false\" data-explanation=\"Digoxin is used for rate control in atrial fibrillation or flutter; it is not utilized for acute termination of ventricular tachycardia.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Digoxin<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">6.<\/span> \n        In the AUGUSTUS trial evaluating patients with Atrial Fibrillation who underwent PCI, which antithrombotic strategy resulted in the lowest rates of bleeding without significantly increasing ischemic events?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"true\" data-explanation=\"The AUGUSTUS trial demonstrated that a regimen of Apixaban plus a P2Y12 inhibitor (without aspirin) caused significantly less bleeding than Vitamin K Antagonist (VKA) regimens or regimens containing aspirin, without a significant penalty in ischemic outcomes.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Apixaban + P2Y12 inhibitor (without Aspirin)<\/button>\n        <button data-correct=\"false\" data-explanation=\"Adding aspirin (triple therapy) significantly increased bleeding risk across all groups in the trial.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Apixaban + P2Y12 inhibitor + Aspirin<\/button>\n        <button data-correct=\"false\" data-explanation=\"VKA regimens had higher bleeding rates compared to the Apixaban regimens.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Warfarin + P2Y12 inhibitor (without Aspirin)<\/button>\n        <button data-correct=\"false\" data-explanation=\"Triple therapy with warfarin was the historical standard but had the highest bleeding rates in the trial.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Warfarin + P2Y12 inhibitor + Aspirin<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">7.<\/span> \n        In intravascular imaging during PCI, Optical Coherence Tomography (OCT) is distinguished from Intravascular Ultrasound (IVUS) by having:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"IVUS has deeper tissue penetration but lower spatial resolution compared to OCT.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Lower spatial resolution and higher tissue penetration<\/button>\n        <button data-correct=\"true\" data-explanation=\"OCT uses near-infrared light, providing approximately 10 times higher spatial resolution (10-20 microns) than IVUS, allowing detailed visualization of thin-cap fibroatheromas and stent struts, but it has much shallower tissue penetration (1-2 mm) and requires blood clearance with contrast.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Higher spatial resolution and lower tissue penetration<\/button>\n        <button data-correct=\"false\" data-explanation=\"OCT has higher resolution but definitely not higher penetration than IVUS.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Higher spatial resolution and higher tissue penetration<\/button>\n        <button data-correct=\"false\" data-explanation=\"This is false; OCT is the gold standard for resolution in intravascular imaging.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Lower spatial resolution and lower tissue penetration<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">8.<\/span> \n        During right and left heart catheterization to differentiate Constrictive Pericarditis from Restrictive Cardiomyopathy, which finding strongly favors Constrictive Pericarditis?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Concordance (both rising and falling together) during respiration suggests restrictive cardiomyopathy.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Concordant changes in LV and RV systolic pressures during respiration<\/button>\n        <button data-correct=\"true\" data-explanation=\"Ventricular interdependence is the hallmark of constriction. During inspiration, RV filling increases, pushing the septum to the left, which decreases LV filling and pressure. This leads to discordant (opposite) changes in RV and LV systolic pressures.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Discordant changes in LV and RV systolic pressures during respiration<\/button>\n        <button data-correct=\"false\" data-explanation=\"LVEDP is typically greater than RVEDP by >5 mmHg in restrictive cardiomyopathy. In constriction, they are usually equalized (within 5 mmHg).&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>C) Left ventricular end-diastolic pressure (LVEDP) exceeding RVEDP by > 5 mmHg<\/button>\n        <button data-correct=\"false\" data-explanation=\"Pulmonary artery systolic pressure > 50 mmHg strongly favors restrictive cardiomyopathy, as constriction rarely causes severe pulmonary hypertension.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>D) Pulmonary artery systolic pressure > 50 mmHg<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">9.<\/span> \n        The Impella device is a percutaneous mechanical circulatory support system. Where must the inlet and outlet of an Impella CP be positioned to function correctly?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"true\" data-explanation=\"The Impella CP is a microaxial pump positioned across the aortic valve. The inlet draws oxygenated blood from the Left Ventricle (LV) and the outlet expels it into the Ascending Aorta, thereby unloading the LV and increasing forward cardiac output.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Inlet in the Left Ventricle, Outlet in the Ascending Aorta<\/button>\n        <button data-correct=\"false\" data-explanation=\"This configuration describes the Impella RP (Right-sided pump) or a TandemHeart setup for right heart support.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Inlet in the Right Atrium, Outlet in the Pulmonary Artery<\/button>\n        <button data-correct=\"false\" data-explanation=\"The Impella does not draw from the left atrium; it crosses the aortic valve into the left ventricle.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Inlet in the Left Atrium, Outlet in the Descending Aorta<\/button>\n        <button data-correct=\"false\" data-explanation=\"Pumping backward from the aorta into the LV would be disastrous (creating massive iatrogenic aortic regurgitation).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Inlet in the Ascending Aorta, Outlet in the Left Ventricle<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">10.<\/span> \n        In patients undergoing Valve-in-Valve (ViV) TAVR for a degenerated surgical aortic bioprosthesis, the most critical anatomical measurement to predict and prevent acute coronary obstruction is the:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"While sinotubular junction width is measured for general TAVR sizing, it is not the primary metric for predicting coronary obstruction in ViV procedures.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Sinotubular junction diameter<\/button>\n        <button data-correct=\"false\" data-explanation=\"Annular perimeter dictates valve sizing, but not the specific risk of the old leaflets occluding the coronaries.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) True annular perimeter<\/button>\n        <button data-correct=\"true\" data-explanation=\"The Virtual to Coronary (VTC) distance estimates the proximity of the projected TAVR device (and the pinned-back old surgical leaflets) to the coronary ostia. A VTC distance < 4 mm carries a very high risk of catastrophic coronary obstruction.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Virtual to Coronary (VTC) distance<\/button>\n        <button data-correct=\"false\" data-explanation=\"LVOT calcium volume predicts the risk of annular rupture and paravalvular leak, not coronary obstruction.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Left ventricular outflow tract (LVOT) calcium volume<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">11.<\/span> \n        Ivabradine reduces heart rate without affecting myocardial contractility or blood pressure. Its unique mechanism of action is:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"true\" data-explanation=\"Ivabradine is a specific inhibitor of the 'funny' current (If) in the sinoatrial (SA) node. By slowing the spontaneous diastolic depolarization phase (Phase 4), it lowers heart rate without negative inotropy.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Inhibition of the If (funny) current in the SA node<\/button>\n        <button data-correct=\"false\" data-explanation=\"This is the mechanism of Non-Dihydropyridine Calcium Channel Blockers (like Diltiazem), which do have negative inotropic effects.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Blockade of L-type calcium channels in the AV node<\/button>\n        <button data-correct=\"false\" data-explanation=\"This is the mechanism of Beta-blockers, which affect both contractility and blood pressure.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Antagonism of Beta-1 adrenergic receptors<\/button>\n        <button data-correct=\"false\" data-explanation=\"Activation of muscarinic receptors (parasympathetic stimulation) reduces HR, but this is not ivabradine's mechanism.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Direct activation of M2 muscarinic receptors<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">12.<\/span> \n        On a standard 12-lead ECG, the presence of an Osborn wave (J wave) is most classically associated with:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Severe hyperkalemia causes peaked T waves, widened QRS, and ultimately a sine wave pattern, not Osborn waves.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Severe hyperkalemia<\/button>\n        <button data-correct=\"false\" data-explanation=\"Brugada syndrome presents with coved ST segment elevation (pseudo-RBBB pattern), not a classic Osborn wave.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Brugada syndrome<\/button>\n        <button data-correct=\"true\" data-explanation=\"The Osborn wave is a prominent positive deflection at the J-point (junction of the QRS complex and ST segment), classically seen in systemic hypothermia.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Systemic hypothermia<\/button>\n        <button data-correct=\"false\" data-explanation=\"Digoxin toxicity classically causes 'scooped' or sagging ST segment depression (Salvador Dali mustache sign).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Digoxin toxicity<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">13.<\/span> \n        In assessing the severity of Mitral Regurgitation (MR) via echocardiography, a vena contracta width greater than or equal to what value is indicative of severe MR?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"0.3 cm is considered mild mitral regurgitation.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) 0.3 cm<\/button>\n        <button data-correct=\"false\" data-explanation=\"0.5 cm falls in the moderate range.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) 0.5 cm<\/button>\n        <button data-correct=\"true\" data-explanation=\"According to ASE guidelines, a vena contracta width of >= 0.7 cm (7 mm) is a highly specific marker for severe mitral regurgitation.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>C) 0.7 cm<\/button>\n        <button data-correct=\"false\" data-explanation=\"While 0.9 cm is definitely severe, 0.7 cm is the threshold established by guidelines.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) 0.9 cm<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">14.<\/span> \n        Which specific imaging modality is the gold standard for diagnosing isolated Cardiac Sarcoidosis by detecting active myocardial inflammation?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"SPECT assesses perfusion and viability but lacks the specificity to identify the active granulomatous inflammation of sarcoidosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Tc-99m Sestamibi SPECT<\/button>\n        <button data-correct=\"false\" data-explanation=\"Tc-99m PYP is the gold standard for diagnosing Transthyretin Cardiac Amyloidosis, not sarcoidosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Tc-99m Pyrophosphate (PYP) scan<\/button>\n        <button data-correct=\"true\" data-explanation=\"18F-FDG PET (often combined with a resting perfusion scan) is the gold standard for identifying the active, glucose-avid inflammatory granulomas characteristic of cardiac sarcoidosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) 18F-FDG PET (Positron Emission Tomography)<\/button>\n        <button data-correct=\"false\" data-explanation=\"While CT angiography can rule out CAD, it does not reliably detect myocardial granulomas.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Coronary CT Angiography<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">15.<\/span> \n        In patients receiving Cardiac Resynchronization Therapy (CRT), approximately what percentage of patients are classified as &#8216;non-responders&#8217; (failing to show clinical or echocardiographic improvement)?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"5% is far too low; finding the optimal LV pacing site and patient selection remains a challenge.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) 5%<\/button>\n        <button data-correct=\"true\" data-explanation=\"Despite adherence to strict guideline indications (LBBB, QRS >150ms), approximately 30% of patients do not experience meaningful clinical or echocardiographic response to CRT, a well-documented phenomenon in EP literature.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>B) 30%<\/button>\n        <button data-correct=\"false\" data-explanation=\"60% non-response would render the therapy ineffective on a population scale, which contradicts major CRT trials showing overall mortality benefits.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) 60%<\/button>\n        <button data-correct=\"false\" data-explanation=\"80% non-response is incorrect. The majority of appropriately selected patients DO respond.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) 80%<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">16.<\/span> \n        During percutaneous coronary intervention (PCI), rotational atherectomy (Rotablator) relies on the principle of &#8216;differential cutting&#8217;. This means the burr preferentially ablates:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Rotational atherectomy is poorly effective on soft, elastic tissue, which simply deflects away from the rapidly spinning burr.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Soft, lipid-rich vulnerable plaques<\/button>\n        <button data-correct=\"true\" data-explanation=\"Differential cutting allows the diamond-coated burr to pulverize hard, inelastic, calcified plaque into microparticles while sparing elastic, normal vessel walls, which simply deflect away from the spinning burr.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Hard, calcified, inelastic plaque<\/button>\n        <button data-correct=\"false\" data-explanation=\"The burr does not selectively target thrombus. Aspiration thrombectomy or mechanical thrombectomy devices are used for fresh clot.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Fresh, red luminal thrombus<\/button>\n        <button data-correct=\"false\" data-explanation=\"Endothelial cells are part of the elastic normal tissue that is generally spared by differential cutting.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Healthy, elastic endothelial cells<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">17.<\/span> \n        The classic hemodynamic definition of Cardiogenic Shock includes a Cardiac Index (CI) and Pulmonary Capillary Wedge Pressure (PCWP) of:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"A CI > 2.2 is generally considered normal or sufficient forward flow.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>A) CI > 2.2 L\/min\/m2 and PCWP < 15 mmHg<\/button>\n        <button data-correct=\"false\" data-explanation=\"This represents hypovolemic shock (low forward flow, but low filling pressures).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) CI < 2.2 L\/min\/m2 and PCWP < 15 mmHg<\/button>\n        <button data-correct=\"true\" data-explanation=\"Cardiogenic shock is defined hemodynamically by inadequate tissue perfusion despite adequate intravascular volume. This is represented by a low Cardiac Index (CI < 2.2) alongside elevated filling pressures (PCWP > 15 mmHg).&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>C) CI < 2.2 L\/min\/m2 and PCWP > 15 mmHg<\/button>\n        <button data-correct=\"false\" data-explanation=\"A CI > 2.2 with a PCWP > 15 represents pulmonary congestion (heart failure) but not necessarily true cardiogenic shock, as forward flow is maintained.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>D) CI > 2.2 L\/min\/m2 and PCWP > 15 mmHg<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">18.<\/span> \n        In adult patients presenting with uncorrected Coarctation of the Aorta, chest radiography classically demonstrates rib notching on the INFERIOR margins of which ribs?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Ribs 1 and 2 are supplied by the costocervical trunk (arising proximal to the coarctation), so they do not develop enlarged collateral flow and are spared from notching.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Ribs 1 and 2<\/button>\n        <button data-correct=\"true\" data-explanation=\"Rib notching in coarctation is caused by dilated, pulsatile intercostal arteries acting as collaterals to bypass the aortic stricture. It classically affects ribs 3 through 8 bilaterally. Ribs 1-2 are spared.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Ribs 3 through 8<\/button>\n        <button data-correct=\"false\" data-explanation=\"The lower ribs (9-12) are rarely involved in the collateral pathway causing classic radiographic notching.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Ribs 9 through 12<\/button>\n        <button data-correct=\"false\" data-explanation=\"Rib notching occurs on the INFERIOR margin of the ribs where the neurovascular bundle runs, not the superior margin.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Superior margins of all ribs<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">19.<\/span> \n        Which of the following adverse effects is uniquely associated with Ticagrelor compared to other P2Y12 inhibitors like Clopidogrel and Prasugrel?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Bleeding is a class effect of all P2Y12 inhibitors, not unique to Ticagrelor.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Gastrointestinal bleeding<\/button>\n        <button data-correct=\"false\" data-explanation=\"Ticlopidine (an older thienopyridine) was associated with neutropenia and TTP, but this is not characteristic of Ticagrelor.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Severe neutropenia<\/button>\n        <button data-correct=\"true\" data-explanation=\"Ticagrelor inhibits adenosine reuptake by RBCs, leading to increased local adenosine levels. This uniquely causes dyspnea (in up to 15-20% of patients) and occasionally bradycardia\/ventricular pauses.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Dyspnea and ventricular pauses<\/button>\n        <button data-correct=\"false\" data-explanation=\"Amiodarone is famous for causing thyroid dysfunction, not Ticagrelor.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Hypothyroidism<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">20.<\/span> \n        What is the requisite pharmacological &#8216;washout&#8217; period when transitioning a heart failure patient from an ACE inhibitor (e.g., Lisinopril) to an ARNI (Sacubitril\/Valsartan) to prevent severe angioedema?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"There is no washout period required when switching from an ARB to an ARNI, but an ACE inhibitor requires a mandatory washout.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) No washout period is required<\/button>\n        <button data-correct=\"false\" data-explanation=\"12 hours is insufficient and poses a high risk of angioedema.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) 12 hours<\/button>\n        <button data-correct=\"true\" data-explanation=\"A strict 36-hour washout period is absolutely required when switching from an ACE inhibitor to Sacubitril\/Valsartan. Both drugs inhibit the breakdown of bradykinin, and overlapping them causes a massive, life-threatening risk of angioedema.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) 36 hours<\/button>\n        <button data-correct=\"false\" data-explanation=\"72 hours is longer than necessary; guidelines strictly stipulate 36 hours.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) 72 hours<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">21.<\/span> \n        In patients with a completely concealed accessory pathway, which of the following arrhythmias is IMPOSSIBLE to occur utilizing the pathway?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Orthodromic AVRT goes down the AV node and UP the accessory pathway (retrograde). Since a concealed pathway conducts retrogradely, this arrhythmia can easily occur.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Orthodromic AVRT<\/button>\n        <button data-correct=\"true\" data-explanation=\"A 'concealed' pathway means it only conducts retrogradely (ventricle to atrium), therefore it does not pre-excite the ventricle (no delta wave). Antidromic AVRT requires the pathway to conduct anterogradely to the ventricles, which is physically impossible in a concealed pathway.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Antidromic AVRT<\/button>\n        <button data-correct=\"false\" data-explanation=\"Atrial fibrillation can occur in anyone, but in a concealed pathway, it will conduct normally down the AV node, resulting in a narrow, irregular QRS.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Atrial fibrillation with a rapid ventricular response<\/button>\n        <button data-correct=\"false\" data-explanation=\"Atrial flutter can also occur, conducting normally down the AV node.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Atrial flutter<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">22.<\/span> \n        The echocardiographic assessment of diastolic function relies heavily on the E\/e&#8217; ratio. A medial E\/e&#8217; ratio greater than what value is highly indicative of elevated left ventricular filling pressures (Grade II or III diastolic dysfunction)?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"An average E\/e' ratio < 8 generally indicates normal LV filling pressures.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) > 8<\/button>\n        <button data-correct=\"false\" data-explanation=\"An E\/e' ratio of 9 to 14 is a 'gray zone' and requires other parameters (TR velocity, LA volume index) to conclude.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) > 10<\/button>\n        <button data-correct=\"true\" data-explanation=\"According to the ASE guidelines, an average E\/e' ratio > 14 (or medial > 15, lateral > 13) is a primary, major criterion indicating elevated left atrial\/LV filling pressures and significant diastolic dysfunction.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>C) > 14<\/button>\n        <button data-correct=\"false\" data-explanation=\"While >20 is definitely elevated, the diagnostic threshold is 14.&#8221; class=&#8221;opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300&#8243;>D) > 20<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">23.<\/span> \n        In patients with suspected cryptogenic stroke, the RESPECT trial provided data supporting the use of percutaneous PFO closure devices primarily for which specific demographic?\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Older patients typically have competing causes for stroke (like subclinical AFib or atherosclerosis), making PFO closure less definitively beneficial.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Patients over the age of 75 with heavy atherosclerotic burden<\/button>\n        <button data-correct=\"true\" data-explanation=\"The RESPECT trial (and long-term follow-up) established that closing a PFO in younger patients (typically < 60 years old) with a cryptogenic ischemic stroke significantly lowers the risk of recurrent stroke compared to medical therapy alone.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Patients under the age of 60 with no other identifiable cause of stroke<\/button>\n        <button data-correct=\"false\" data-explanation=\"PFO closure is contraindicated and useless for stroke prevention if the patient has documented Atrial Fibrillation (they need anticoagulation).\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Patients with paroxysmal atrial fibrillation who cannot tolerate anticoagulation<\/button>\n        <button data-correct=\"false\" data-explanation=\"Migraine relief is an oft-reported secondary effect, but it is not an FDA-approved indication for PFO closure.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Patients with severe migraines with aura, without prior stroke<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">24.<\/span> \n        Loeffler endocarditis is a restrictive cardiomyopathy uniquely characterized by severe endomyocardial fibrosis and the presence of:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"Non-caseating granulomas are the hallmark of Cardiac Sarcoidosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) Non-caseating granulomas<\/button>\n        <button data-correct=\"false\" data-explanation=\"Apple-green birefringence with Congo red stain defines Cardiac Amyloidosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) Apple-green birefringence on Congo red stain<\/button>\n        <button data-correct=\"true\" data-explanation=\"Loeffler endocarditis (a form of hypereosinophilic syndrome) involves massive infiltration of eosinophils into the myocardium, releasing toxic granular contents that cause severe endocardial necrosis followed by thick, restrictive fibrosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) Peripheral and myocardial eosinophilia<\/button>\n        <button data-correct=\"false\" data-explanation=\"Iron deposition in the myocardium is characteristic of Hemochromatosis.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) Extensive iron deposition in the myocytes<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"mcq-card bg-slate-900 border border-slate-800 rounded-2xl p-5 md:p-6 shadow-md transition-all duration-300 hover:border-cyan-800\/50\" data-answered=\"false\">\n      <h3 class=\"text-lg md:text-xl font-bold text-slate-100 mb-5 leading-snug flex gap-3\">\n        <span class=\"text-cyan-500 font-black\">25.<\/span> \n        The ISCHEMIA trial randomized patients with moderate-to-severe stable ischemia to a routine invasive strategy (angiography + revascularization) versus a conservative medical strategy. The primary outcome concluded that:\n      <\/h3>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-2\">\n        <button data-correct=\"false\" data-explanation=\"The trial actually showed the opposite; invasive strategy did NOT reduce mortality.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">A) The invasive strategy significantly reduced all-cause mortality<\/button>\n        <button data-correct=\"true\" data-explanation=\"The ISCHEMIA trial showed that in stable patients, an initial routine invasive strategy did not reduce the risk of ischemic cardiovascular events or death compared to optimal medical therapy, although it did provide better symptomatic relief for angina.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">B) There was no significant difference in the composite of CV death, MI, or hospitalization for HF\/unstable angina between the two strategies<\/button>\n        <button data-correct=\"false\" data-explanation=\"The medical therapy group did not suffer a higher rate of fatal myocardial infarctions; rates of the primary composite endpoint were similar.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">C) The conservative strategy resulted in a significantly higher rate of fatal MI<\/button>\n        <button data-correct=\"false\" data-explanation=\"Both groups received aggressive optimal medical therapy (statins, antiplatelets, anti-anginals). The difference was the use of upfront catheterization.\" class=\"opt-btn w-full text-left p-4 rounded-xl border border-slate-700 bg-slate-950 hover:bg-slate-800 transition-all text-sm md:text-base font-semibold text-slate-300\">D) The invasive strategy was only beneficial in patients with LVEF < 35%<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm leading-relaxed mt-4\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  document.addEventListener('DOMContentLoaded', () => {\n    const cards = document.querySelectorAll('.mcq-card');\n    const scoreCorrectEl = document.getElementById('score-correct');\n    const scoreAnsweredEl = document.getElementById('score-answered');\n    const progressBar = document.getElementById('progress-bar');\n    \n    let correctCount = 0;\n    let answeredCount = 0;\n    const totalQuestions = cards.length;\n\n    cards.forEach(card => {\n      const buttons = card.querySelectorAll('.opt-btn');\n      const feedbackBox = card.querySelector('.feedback-box');\n\n      buttons.forEach(btn => {\n        btn.addEventListener('click', function() {\n          \n          \/\/ Prevent multiple answers on the same question\n          if (card.dataset.answered === 'true') return;\n          card.dataset.answered = 'true';\n          \n          answeredCount++;\n          \n          const isCorrect = this.dataset.correct === 'true';\n          const explanationText = this.dataset.explanation;\n\n          \/\/ Update Scoreboard UI\n          scoreAnsweredEl.innerText = answeredCount;\n          progressBar.style.width = `${(answeredCount \/ totalQuestions) * 100}%`;\n\n          if (isCorrect) {\n            correctCount++;\n            scoreCorrectEl.innerText = correctCount;\n          }\n\n          \/\/ Apply styling to buttons\n          buttons.forEach(b => {\n            b.disabled = true;\n            b.classList.remove('hover:bg-slate-800', 'cursor-pointer');\n            b.classList.add('opacity-50', 'cursor-not-allowed');\n            \n            \/\/ Highlight the correct answer no matter what\n            if (b.dataset.correct === 'true') {\n              b.classList.remove('opacity-50', 'bg-slate-950', 'border-slate-700');\n              b.classList.add('opacity-100', 'bg-teal-950', 'border-teal-500', 'text-teal-300');\n              b.innerHTML += ' <span class=\"float-right text-teal-400 font-bold tracking-wider\">\u2713<\/span>';\n            }\n          });\n\n          \/\/ Highlight the clicked wrong answer\n          if (!isCorrect) {\n            this.classList.remove('opacity-50', 'bg-slate-950', 'border-slate-700');\n            this.classList.add('opacity-100', 'bg-rose-950', 'border-rose-500', 'text-rose-300');\n            this.innerHTML += ' <span class=\"float-right text-rose-400 font-bold tracking-wider\">\u2717<\/span>';\n          }\n\n          \/\/ Render the feedback box\n          feedbackBox.innerHTML = `\n            <div class=\"font-extrabold uppercase tracking-widest text-xs mb-1.5 ${isCorrect ? 'text-teal-400' : 'text-rose-400'}\">\n              ${isCorrect ? 'Correct!' : 'Incorrect'}\n            <\/div>\n            <p class=\"m-0 text-slate-300\">${explanationText}<\/p>\n          `;\n          \n          feedbackBox.classList.remove('hidden');\n          feedbackBox.classList.add(\n            'block', \n            isCorrect ? 'bg-teal-950\/30' : 'bg-rose-950\/30', \n            'border', \n            isCorrect ? 'border-teal-900\/50' : 'border-rose-900\/50'\n          );\n        });\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>Please ignore the questions with incomplete options as they have errors in code! Advanced Clinical Series Cardiology MCQs: Part 9 Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials. Live Score 0 \/ 25 Progress 0\/25 1. In the cardiac catheterization lab, measuring the instantaneous wave-free ratio (iFR) is often preferred over [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":67951,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[3,9],"tags":[],"class_list":["post-67950","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology-mcq","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Series of Interactive Cardiology MCQs 9 - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Series of Interactive Cardiology MCQs 9 - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"Please ignore the questions with incomplete options as they have errors in code! Advanced Clinical Series Cardiology MCQs: Part 9 Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials. Live Score 0 \/ 25 Progress 0\/25 1. In the cardiac catheterization lab, measuring the instantaneous wave-free ratio (iFR) is often preferred over [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-23T01:15:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-23T01:39:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1261\" \/>\n\t<meta property=\"og:image:height\" content=\"702\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"New Series of Interactive Cardiology MCQs 9\",\"datePublished\":\"2026-10-23T01:15:38+00:00\",\"dateModified\":\"2026-10-23T01:39:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/\"},\"wordCount\":1222,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg\",\"articleSection\":[\"Cardiology MCQ\",\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/\",\"name\":\"New Series of Interactive Cardiology MCQs 9 - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg\",\"datePublished\":\"2026-10-23T01:15:38+00:00\",\"dateModified\":\"2026-10-23T01:39:32+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg\",\"width\":1261,\"height\":702},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/new-series-of-interactive-cardiology-mcqs-9\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Series of Interactive Cardiology MCQs 9\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Series of Interactive Cardiology MCQs 9 - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/","og_locale":"en_US","og_type":"article","og_title":"New Series of Interactive Cardiology MCQs 9 - All About Cardiovascular System and Disorders","og_description":"Please ignore the questions with incomplete options as they have errors in code! Advanced Clinical Series Cardiology MCQs: Part 9 Master-level assessment spanning complex hemodynamics, electrophysiology, structural interventions, and landmark clinical trials. Live Score 0 \/ 25 Progress 0\/25 1. In the cardiac catheterization lab, measuring the instantaneous wave-free ratio (iFR) is often preferred over [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-10-23T01:15:38+00:00","article_modified_time":"2026-10-23T01:39:32+00:00","og_image":[{"width":1261,"height":702,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"New Series of Interactive Cardiology MCQs 9","datePublished":"2026-10-23T01:15:38+00:00","dateModified":"2026-10-23T01:39:32+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/"},"wordCount":1222,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg","articleSection":["Cardiology MCQ","General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/","url":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/","name":"New Series of Interactive Cardiology MCQs 9 - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg","datePublished":"2026-10-23T01:15:38+00:00","dateModified":"2026-10-23T01:39:32+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/10\/New-Series-of-Interactive-Cardiology-MCQs-9.jpg","width":1261,"height":702},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/new-series-of-interactive-cardiology-mcqs-9\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"New Series of Interactive Cardiology MCQs 9"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=67950"}],"version-history":[{"count":2,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67950\/revisions"}],"predecessor-version":[{"id":67953,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/67950\/revisions\/67953"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/67951"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=67950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=67950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=67950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}